Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Huahai Pharmaceutical Co's Days Inventory or its related term are showing as below:
SHSE:600521'
s Days Inventory Range Over the Past 10 Years
Min: 214.06 Med: 353.27 Max: 380.08
Current: 372.53
During the past 13 years, Zhejiang Huahai Pharmaceutical Co's highest Days Inventory was 380.08. The lowest was 214.06. And the median was 353.27.
SHSE:600521's Days Inventory is ranked worse than 91.01% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs SHSE:600521: 372.53
Inventory Turnover measures how fast the company turns over its inventory within a year.
Zhejiang Huahai Pharmaceutical Co's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Zhejiang Huahai Pharmaceutical Co's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.58.
Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Zhejiang Huahai Pharmaceutical Co's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Zhejiang Huahai Pharmaceutical Co's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Zhejiang Huahai Pharmaceutical Co Days Inventory Related Terms
Zhejiang Huahai Pharmaceutical Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Huahai Pharmaceutical Co Days Inventory Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Huahai Pharmaceutical Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Huahai Pharmaceutical Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Huahai Pharmaceutical Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Zhejiang Huahai Pharmaceutical Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Huahai Pharmaceutical Co (SHSE:600521) has a Days Inventory of 339.58 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Zhejiang Huahai Pharmaceutical Co and its competitors. This is near median its historical median of 353.27. Over the past decade, Zhejiang Huahai Pharmaceutical Co's Days Inventory has ranged from 214.06 to 380.08. According to the industry distribution chart, Zhejiang Huahai Pharmaceutical Co ranks #840 out of 923 companies in the Drug Manufacturers industry, placing it in the top 91%.
Is Zhejiang Huahai Pharmaceutical Co's Days Inventory too high?
Zhejiang Huahai Pharmaceutical Co's current Days Inventory of 339.58 is near median its 10-year median of 353.27. Over the past 10 years, this metric has ranged from a low of 214.06 to a high of 380.08. The Drug Manufacturers industry median Days Inventory is 164.87. Zhejiang Huahai Pharmaceutical Co's value of 339.58 is 106% above this industry median. Based on the distribution chart, Zhejiang Huahai Pharmaceutical Co ranks #840 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Huahai Pharmaceutical Co has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Huahai Pharmaceutical Co's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Huahai Pharmaceutical Co ranks #840 out of 923 companies for Days Inventory. This places Zhejiang Huahai Pharmaceutical Co in the lower half of its industry. The industry median Days Inventory is 164.87. Zhejiang Huahai Pharmaceutical Co's value of 339.58 is 106% above this benchmark. Historically, Zhejiang Huahai Pharmaceutical Co's own Days Inventory has ranged from 214.06 to 380.08 over the past decade. While the company's 10-year median is 353.27 vs. the industry median of 164.87, Zhejiang Huahai Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Huahai Pharmaceutical Co's current Days Inventory of 339.58 is 106% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Zhejiang Huahai Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Huahai Pharmaceutical Co's current Days Inventory is 339.58, which is near median its own 10-year median of 353.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Huahai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co (SHSE:600521) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.49, compared to a current price of ¥16.77 — trading 1.7% above its estimated fair value. The current Days Inventory is 339.58, which is near median its 10-year median of 353.27 and 106% above the Drug Manufacturers industry median of 164.87. Zhejiang Huahai Pharmaceutical Co's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Zhejiang Huahai Pharmaceutical Co (SHSE:600521), the current Days Inventory is 339.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Huahai Pharmaceutical Co (SHSE:600521) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Huahai Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥16.77 is trading 1.7% above its estimated GF Value™ of ¥16.49.
GuruFocus considers Zhejiang Huahai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600521:
Days Inventory: 339.58 (near median its 10-year median of 353.27)
GF Value™: ¥16.49 vs. price of ¥16.77 (1.7% above fair value)
Industry Position: 106% above the Drug Manufacturers median (#840 of 923)
No single metric tells the full story. See the SHSE:600521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
87GF Score
Get the complete analysis for SHSE:600521
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600521 has been successfully added to your 
